홈 카테고리 맞춤형시장조사 국제컨퍼런스 글로벌 파트너 메일링 서비스 회사소개회사소개 Contact Us
English Japaness Chinese
Home > 시장보고서 > 파머슈티컬 > 감염질환 > The Global Influenza Market
카테고리
파머슈티컬 (4931)
감염질환 (349)
골질환 치료 (38)
당뇨병 (194)
백신 (181)
비만치료/다이어트 (44)
비처방 의약품 (152)
수의학 (17)
신경질환 (174)
신약개발 (1529)
암치료 (941)
약물전달 (185)
의약품 규제환경 (127)
정신질환 (86)
제네릭 의약품 (128)
제약회사분석 (523)
처방약 (165)
시장보고서

The Global Influenza Market

리서치사 BCC Research
발행일 2009년 08월 상품코드 99390
페이지 정보 144 pages
가격
US $ 4,850 ￦ 5,778,700 PDF by E-mail (Single User License)
US $ 5,950 ￦ 7,089,400 PDF by E-mail (Business Unit License)
US $ 8,500 ￦ 10,127,700 PDF by E-mail (Enterprise License)


영문목차

Abstract

THIS REPORT:

Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2014 Identifies markets in the segments of vaccines/therapeutics and diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis Covers some of the most significant issues, trends and market factors Profiles the top companies and major players in the market.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, The Global Influenza Market: Vaccines, Therapeutics, and Diagnostics is an update to the BCC Research report published in 2006 titled, The Worldwide Influenza Market (PHM049A). This report provides an overview of products currently in the marketplace and a detailed analysis of market position and competitive environments. The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. There is a special emphasis on U.S. and European markets.

REASONS FOR DOING THE STUDY

Annually, up to a half - million people die of influenza and, with the threat of a pandemic, government agencies and disease prevention organizations are devoted to gaining control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next 5 years will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.

SCOPE OF REPORT

This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts, and competitive analyses. Additionally, the study covers some of the most significant issues and trends and market factors.

METHODOLOGY

The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments, and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature, and various business journals that have emphasis on influenza products, technology and related information.

Market data for this report pertains to the worldwide market, with specific U.S. data included. All information is displayed using U.S. dollars at the manufacturers' level. The base year of the report is 2009, with historical data provided for 2007 and 2008, and forecast data provided through 2014. Historical, base year, and forecast data are provided for each market segment of the report. Compound annual growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the 2009 base year.

Table of Contents

Chapter- 1: INTRODUCTION -- Complimentary 3

  • STUDY GOALS AND OBJECTIVES 1
  • REASONS FOR DOING THE STUDY 1
  • SCOPE OF REPORT 1
  • METHODOLOGY 2
  • RELATED BCC STUDIES 2
  • ANALYST CREDENTIALS 3
  • BCC ONLINE SERVICES 3
  • DISCLAIMER 3

Chapter-2: SUMMARY 2

  • THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY 4
  • SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2014 ($ MILLIONS) 5
  • SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2014 ($ MILLIONS) 5

Chapter-3: INDUSTRY OVERVIEW 17

  • OVERVIEW 6
  • HISTORY OF THE MARKET 6
  • EPIDEMICS/PANDEMICS 6
  • Spanish Influenza 1918 - 1919 6
  • Asian Influenza 1957 7
  • Hong Kong Influenza 1968 7
  • Swine Flu 1976 7
  • Russian Influenza 1977 7
  • Avian Flu 1961, 1997, 2003 - 2009 (sporadic) 8
  • Novel Influenza H1N1 2009 8
  • VIRUS MUTATIONS 9
  • TYPES OF INFLUENZA 9
  • Influenza Type A 10
  • Influenza A H5 10
  • Influenza A H7 10
  • Influenza A H9 10
  • Influenza A H1 10
  • Influenza Type B 11
  • Influenza Type C 11
  • WORLD ACTIVITY OF INFLUENZA VIRUSES 11
  • TABLE 1 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE 11
  • TABLE 1 (CONTINUED) 12
  • THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE 13
  • WORLD HEALTH ORGANIZATION 13
  • CENTERS FOR DISEASE CONTROL AND PREVENTION 13
  • American Recovery and Reinvestment Act (ARRA) of 2009 14
  • U.S. VIRAL SURVEILLANCE 14
  • TABLE 2 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005 - 2009 FLU SEASONS 15
  • VACCINE RECOMMENDATIONS 15
  • TABLE 3 THIMEROSAL CONTENT OF INFLUENZA VACCINES 16
  • TABLE 4 CDC INFLUENZA VACCINE RECOMMENDATIONS 17
  • DEVELOPMENT OF FLU VACCINES 17
  • TABLE 5 MIDAS RESEARCH TEAMS AND AREAS OF STUDY 18
  • UNIVERSAL VACCINE 18
  • WORLD DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY 18
  • TABLE 6 ESTIMATED WORLD POPULATION AND ANNUAL GROWTH, BY SELECTED AGE GROUP AND SELECTED YEARS THROUGH 2030 (# MILLIONS) 19
  • FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS 2000 - 2030 (# MILLIONS) 19
  • TABLE 7 POPULATION BY SELECTED COUNTRIES, THROUGH 2014 (MILLIONS) 20
  • FIGURE 2 POPULATION BY SELECTED COUNTRIES, 2007 - 2014 ($ MILLIONS) 21
  • TABLE 8 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2009 DATA AND POPULATION 21
  • TABLE 9 UNITED STATES VIRAL STATISTICS, ESTIMATED ON 2009 DATA AND POPULATION 22

Chapter-4: ISSUES AFFECTING THE MARKET 23

  • H1N1 OUTBREAK 2009 (SWINE FLU) 23
  • DIAGNOSTICS 23
  • AVIAN FLU 24
  • U.S. GOVERNMENT INTERVENTION 24
  • TABLE 10 COUNTRIES AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS 25
  • AVIAN FLU SURVEILLANCE 26
  • TABLE 11 WHO - REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS 26
  • FIGURE 3 WHO - REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS, 2003-2009 27
  • THE WHO AND CONTAINMENT ISSUES FOR PANDEMIC INFLUENZA 27
  • TABLE 12 APPROVED WHO INFLUENZA CENTERS BY REGION 28
  • TABLE 12 (CONTINUED) 29
  • TABLE 12 (CONTINUED) 30
  • TABLE 12 (CONTINUED) 31
  • TABLE 12 (CONTINUED) 32
  • TABLE 12 (CONTINUED) 33
  • TABLE 12 (CONTINUED) 34
  • TABLE 13 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003-MAY 2009 (SUBTYPE H5N1 IN POULTRY) 35
  • TABLE 13 (CONTINUED) 36
  • FIGURE 4 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE (%) 36
  • FIGURE 4 (CONTINUED) 37
  • INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS 37
  • PRE - PANDEMIC VACCINATION 37
  • ANTIVIRAL RESISTANCE 38
  • U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE' S (HHS) CONTRACTS FOR INFLUENZA PREPAREDNESS 38
  • TABLE 14 ORDERS OF BULK SUPPLY NOVEL H1N1 VACCINE ANTIGEN AND ADJUVANT, 2009 ($ MILLIONS) 39
  • BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) 39
  • HHS CONTRACTS FOR RELATED TECHNOLOGIES 39
  • PREVIOUS U.S. VACCINE CONTRACTS 40
  • RECREATED VIRUSES 40
  • IMMATERIALIZED MARKET RISK 41
  • MEDIA COVERAGE AND VACCINATIONS 42
  • EPIDEMIC/PANDEMIC THREAT 42
  • TABLE 15 ESTIMATED INCIDENCE OF NOVEL H1N1 INFLUENZA FOR 2009 SECOND WAVE IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS) 43
  • TABLE 15 (CONTINUED) 44
  • WORLD INFLUENZA IMAPCT 45
  • SEASONAL FLU ECONOMIC IMPACT IN THE U.S. 45
  • HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC 45

Chapter-5: PATENT ANALYSIS 10

  • OVERVIEW 46
  • INFLUENZA PATENTS BY PATENT NUMBER 46
  • TABLE 16 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER 47
  • TABLE 16 (CONTINUED) 48
  • TABLE 16 (CONTINUED) 49
  • TABLE 17 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 50
  • FIGURE 5 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR 51
  • ABBOTT LABORATORIES 52
  • AMGEN 52
  • MEDIMMUNE/AVIRON 52
  • BAXTER HEALTHCARE 53
  • BIOTA SCIENTIFIC 53
  • CONNAUGHT LABORATORIES, INC. 53
  • CRUCELL HOLLAND B.V. 54
  • GLAXOSMITHKLINE 54
  • MERCK & CO. INC. 54
  • NOVARTIS VACCINES/CHIRON 55
  • PROTEIN SCIENCES CORP. 55
  • YEDA RESEARCH AND DEVELOPMENT 55

Chapter-6: INFLUENZA THERAPIES/VACCINES 37

  • OVERVIEW 56
  • CURRENT VACCINES 56
  • CSL BIOTHERAPIES 56
  • GLAXOSMITHKLINE 57
  • MEDIMMUNE 57
  • NOVARTIS 57
  • SANOFI PASTEUR 58
  • SOLVAY PHARMACEUTICALS 58
  • TABLE 18 MARKETED VACCINE PRODUCTS, THROUGH 2009 58
  • SEASONAL 2008/2009 VACCINE APPROVALS 59
  • TABLE 19 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2008 - 2009 INFLUENZA SEASON 59
  • CURRENT THERAPIES 59
  • TABLE 20 MARKETED THERAPIES, THROUGH 2009 60
  • SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS 60
  • TABLE 21 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY AGE: UNITED STATES 60
  • TABLE 21 (CONTINUED) 61
  • GENERIC AVAILABILITY 62
  • TABLE 22 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS 62
  • VACCINE AND BIOLOGICAL DEVELOPMENTS 62
  • ACAMBIS PLC 62
  • ALNYLAM PHARMACEUTICALS 63
  • ALPHAVAX 63
  • BIOCRYST PHARMACEUTICALS 63
  • BIONDVAX 63
  • BIOTA HOLDINGS AND SANKYO COMPANY, LTD. 63
  • CRUCELL 64
  • CURELAB 64
  • CYTOGENIX 64
  • DYNAVAX TECHNOLOGIES 64
  • GENEREX BIOTECHNOLOGY, 65
  • GLAXOSMITHKLINE 65
  • HEMISPHERX BIOPHARMA 65
  • IMMUNEREGEN BIOSCIENCES, INC. 66
  • INTERCELL 66
  • MEDIMMUNE 66
  • NANOVIRICIDES, INC. 66
  • NEXBIO, INC. 67
  • NOBILON 67
  • NOVARTIS VACCINES 67
  • NOVAVAX, INC. 67
  • PROTEIN SCIENCES CORPORATION 68
  • SANOFI PASTEUR 68
  • SOLVAY PHARMACEUTICALS 68
  • SINOVAC BIOTECH 69
  • TOYAMA CHEMICAL 69
  • VAXIN, INC.' S 69
  • VAXINNATE 69
  • VICAL, INC. 69
  • TABLE 23 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS 70
  • TABLE 23 (CONTINUED) 71
  • TABLE 23 (CONTINUED) 72
  • CLINICAL TRIALS 72
  • TABLE 24 CLINICAL TRIALS FOR INFLUENZA BY SELECTED COUNTRY AND TRIAL STATUS 73
  • FIGURE 6 CLINICAL TRIALS FOR INFLUENZA BY SELECTED COUNTRY AND TRIAL STATUS 73
  • RECENT INDUSTRY NEWS 74
  • MARKET ANALYSIS 74
  • TABLE 25 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY MARKET, THROUGH 2014 ($ MILLIONS) 75
  • FIGURE 7 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY MARKET, 2007-2014 ($ MILLIONS) 75
  • TABLE 26 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 76
  • FIGURE 8 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2007-2014 ($ MILLIONS) 76
  • THE GLOBAL INFLUENZA VACCINE MARKET 77
  • TABLE 27 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 77
  • FIGURE 9 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 78
  • TABLE 28 UNITS FOR INFLUENZA VACCINES BY PRODUCT AND MANUFACTURER, 2005 - 2008 (MILLIONS) 79
  • FIGURE 10 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2005 - 2006 SEASON (MILLIONS) 79
  • FIGURE 11 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2006 - 2007 SEASON (MILLIONS) 80
  • FIGURE 12 UNITS FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2008 SEASON (MILLIONS) 80
  • The U.S. Influenza Vaccine Market 81
  • TABLE 29 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 82
  • FIGURE 13 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 82
  • TABLE 30 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005 - 2009 83
  • FIGURE 14 ESTIMATED TOTAL UNITS SHIPPED TO THE UNITED STATES BY SEASON, 2005 - 2009 83
  • TABLE 31 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008 - 2009 (UNITS PER MILLION) 84
  • FIGURE 15 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE UNITED STATES BY MANUFACTURER, 2008 - 2009 SEASON (%) 84
  • The European Influenza Vaccine Market 84
  • TABLE 32 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 85
  • FIGURE 16 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 85
  • THE GLOBAL INFLUENZA THERAPEUTICS MARKET 86
  • TABLE 33 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 86
  • FIGURE 17 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 87
  • Influenza Therapeutics Market in the United States 87
  • TABLE 34 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 87
  • FIGURE 18 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 88
  • Influenza Therapeutics Market in Europe 88
  • TABLE 35 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 88
  • FIGURE 19 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 89
  • COMPETITOR ANALYSIS 89
  • COMPETITOR ANALYSIS (CONTINUED) 90
  • TABLE 36 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007 - 2009 (%) 91
  • FIGURE 20 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2007 (%) 91
  • FIGURE 21 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2008 (%) 92
  • FIGURE 22 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, BASED ON GLOBAL REVENUES, 2009 (%) 92

Chapter-7: INFLUENZA DIAGNOSTICS 15

  • OVERVIEW 93
  • TABLE 37 INFLUENZA DIAGNOSTIC TABLE 93
  • TABLE 37 (CONTINUED) 94
  • PRODUCT DESCRIPTION 94
  • Conventional Laboratory Tests 94
  • Applied Biosystems 94
  • Qiagen, Inc. 95
  • TABLE 38 EXAMPLES OF CONVENTIONAL LABORATORY TESTS FOR INFLUENZA 95
  • Rapid Testing 96
  • 3M and Response Biomedical 96
  • Becton Dickinson 96
  • Diagnostic Hybrids 97
  • Genzyme Diagnostics 97
  • Inverness Laboratories 97
  • Luminex 97
  • Prodesse, Inc. 98
  • Quidel 98
  • Remel, Inc. 98
  • SA Scientific, Ltd. 98
  • TABLE 39 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH JUNE 2009 99
  • TABLE 40 RAPID INFLUENZA TESTS AVERAGE PRICE ($) 100
  • LABORATORY SERVICES 100
  • Associated Regional University Pathologists (ARUP) Laboratories 100
  • Bio - Reference Laboratories, Inc 100
  • Laboratory Corporation of America 101
  • Pathology Associates Medical Laboratories 101
  • Quest Diagnostics 101
  • Specialty Laboratories 102
  • ViroMed Laboratories, Inc. 102
  • TABLE 41 PROVIDERS OF TEST SERVICES 102
  • INDUSTRY DEVELOPMENTS 102
  • MARKET ANALYSIS 103
  • TABLE 42 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, THROUGH 2014 ($ MILLIONS) 104
  • FIGURE 23 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, 2007-2014 ($ MILLIONS) 104
  • TABLE 43 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 105
  • FIGURE 24 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2007-2014 ($ MILLIONS) 106
  • MANUFACTURER REVENUES 106
  • TABLE 44 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 107
  • FIGURE 25 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY MANUFACTURER, 2007 - 2009 ($ MILLIONS) 107

Chapter-8: MARKET SUMMARY 3

  • TOTAL MARKET ANALYSIS 108
  • TABLE 45 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2014 ($ MILLIONS) 109
  • FIGURE 26 GLOBAL INFLUENZA MARKET ANALYSIS, BY REVENUE SEGMENT, 2007-2014 ($ MILLIONS) 109
  • INDUSTRY PARTICIPANTS 109
  • TABLE 46 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE 110

Chapter-9: COMPANY PROFILES 17

  • ASTRAZENECA/MEDIMMUNE 111
  • TABLE 47 ASTRAZENECA' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 112
  • FIGURE 27 ASTRAZENECA' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 112
  • BECTON DICKINSON 113
  • TABLE 48 BECTON DICKINSON' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 113
  • FIGURE 28 BECTON DICKINSON' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 114
  • CSL BIOTHERAPIES 114
  • TABLE 49 CSL LIMITED' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 115
  • FIGURE 29 CSL LIMITED' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 115
  • GLAXOSMITHKLINE 116
  • TABLE 50 GLAXOSMITHKLINE' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 117
  • FIGURE 30 GLAXOSMITHKLINE' S COMPANY REVENUES 2006 - 2009 ($ MILLIONS) 117
  • INVERNESS MEDICAL 117
  • TABLE 51 INVERNESS MEDICAL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 118
  • FIGURE 31 INVERNESS MEDICAL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 118
  • NOVARTIS VACCINES AND DIAGNOSTICS 119
  • TABLE 52 NOVARTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 120
  • FIGURE 32 NOVARTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 120
  • QUIDEL 121
  • TABLE 53 QUIDEL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 121
  • FIGURE 33 QUIDEL' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 122
  • ROCHE 122
  • TABLE 54 ROCHE GROUP' S REVENUES, 2006 - 2009 ($ MILLIONS) 123
  • FIGURE 34 ROCHE GROUP' S REVENUES, 2006 - 2009 ($ MILLIONS) 124
  • SANOFI - AVENTIS/SANOFI PASTEUR 124
  • SANOFI - AVENTIS/SANOFI PASTEUR (CONTINUED) 125
  • TABLE 55 SANOFI - AVENTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 126
  • FIGURE 35 SANOFI - AVENTIS' COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 126
  • SOLVAY 126
  • TABLE 56 SOLVAY' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 127
  • FIGURE 36 SOLVAY' S COMPANY REVENUES, 2006 - 2009 ($ MILLIONS) 127

Chapter-10: APPENDIX 17

  • APPENDIX 128
  • MANUFACTURERS AND DEVELOPERS 128
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 129
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 130
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 131
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 132
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 133
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 134
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 135
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 136
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 137
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 138
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 139
  • MANUFACTURERS AND DEVELOPERS (CONTINUED) 140
  • MENTIONED UNIVERSITIES 141
  • RELEVANT ASSOCIATIONS AND ORGANIZATIONS 142
  • RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED) 143
  • RELEVANT ASSOCIATIONS AND ORGANIZATIONS (CONTINUED) 144
Back to Top